An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes
S Shams' ili, J De Beukelaar, JW Gratama… - Journal of …, 2006 - Springer
S Shams' ili, J De Beukelaar, JW Gratama, H Hooijkaas, M Van Den Bent, M van't Veer…
Journal of neurology, 2006•SpringerAnti-CD20 monoclonal antibody (rituximab) is effectively used in the treatment of B-cell
lymphomas. Recent reports in the literature suggest that antibody associated autoimmune
disorders may respond to rituximab. We therefore treated nine patients with anti-Hu or anti-
Yo associated paraneoplastic neurological syndromes (PNS) with a maximum of four
monthly IV infusions of rituximab (375mg/m 2). In this uncontrolled, unblinded trial of
rituximab, three patients improved≥ 1 point on the Rankin Scale (RS). One patient with …
lymphomas. Recent reports in the literature suggest that antibody associated autoimmune
disorders may respond to rituximab. We therefore treated nine patients with anti-Hu or anti-
Yo associated paraneoplastic neurological syndromes (PNS) with a maximum of four
monthly IV infusions of rituximab (375mg/m 2). In this uncontrolled, unblinded trial of
rituximab, three patients improved≥ 1 point on the Rankin Scale (RS). One patient with …
Abstract
Anti-CD20 monoclonal antibody (rituximab) is effectively used in the treatment of B-cell lymphomas. Recent reports in the literature suggest that antibody associated autoimmune disorders may respond to rituximab. We therefore treated nine patients with anti-Hu or anti-Yo associated paraneoplastic neurological syndromes (PNS) with a maximum of four monthly IV infusions of rituximab (375mg/m2). In this uncontrolled, unblinded trial of rituximab, three patients improved ≥1 point on the Rankin Scale (RS). One patient with limbic encephalitis improved dramatically (RS from 5 to 1). Further studies of rituximab in autoantibody associated PNS are warranted.
Springer